Skip to main content

Table 1 Summary of antitumor activity of lenvatinib in seven subcutaneous xenograft models

From: Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

Tumor cell

IC501)(μM)

TV2)(mm3)

ΔTV (%)3)lenvatinib (mg/kg)

1

3

10

30

100

MDA-MB 4354) (Melanoma)

24.2

180

55.7*

56.9*

40.2*

21.2*

25.7*

MIApaca-II5) (Pancreas)

33.8

250

56.1*

49.9*

30.1*

15.3*

12.5*

H4605) (Lung)

26.3

110

65.4

34.9*

16.3*

16.4*

-0.8*

SK-OV-35) (Ovary)

26.4

230

52.3*

39.6*

12.2*

8.3*

-15.6*

Colo2055) (Colon)

27.5

320

43.8*

23.1*

12.8*

-4.5*

-21.3*

A4315) (Epidermoid)

30.8

310

41.7

29.4*

0.0*

-7.5*

-32.9*

DU1454) (Prostate)

30.8

160

-7.5*

-42.2*

-65.4*

-72.0*

-78.6*

  1. 1)In vitro anti-proliferative activity of lenvatinib.
  2. 2)Lenvatinib treatments started at indicated tumor volumes.
  3. 3)ΔT/C of individual mice was determined first, and then an mean value was calculated.
  4. 4)Lenvatinib was orally administered twice daily for 28 days.
  5. 5)Lenvatinib was orally administered twice daily for 14 days.
  6. *p < 0.05 versus vehicle control.
Back to article page

Vascular Cell

ISSN: 2045-824X

Contact us